Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582031 | 0.82 | KIT (0.43) | ALDH1A1TSHRMAPK1KMT2AHSD17B10 | |
| SCHEMBL24036416 | 0.79 | KDM5B (0.39) | ALDH1A1TSHRMAPK1KMT2AHSD17B10 | |
| SCHEMBL22061450 | 0.79 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPK1KMT2AHSD17B10 | |
| SCHEMBL9274705 | 0.79 | KIT (0.33) | ALDH1A1TSHRMAPK1KMT2AHSD17B10 | |
| SCHEMBL673370 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1KMT2AHSD17B10 | |
| SCHEMBL29640756 | 0.77 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL27711325 | 0.75 | ELANE (0.36) | ALDH1A1F2PLAUKLKB1ELANE | |
| SCHEMBL26627922 | 0.75 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL13061839 | 0.74 | KCNH2 (0.30) | — | |
| SCHEMBL9279870 | 0.74 | GSK3A (0.36) | ALDH1A1MAPK1KMT2AHSD17B10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289821-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| EP-3852748-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4596543-A2 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Organovo, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-113056271-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | ORGANOVO, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210395253-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-12-23 | — | — | US | disclosed |
| US-11084817-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113056271-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2021021893-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | ALDH1A1 2205/4885TSHR 365/4885MAPK1 3269/4885 |
| US-20210395253-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | ALDH1A1 2205/4885TSHR 365/4885MAPK1 3269/4885 |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | ALDH1A1 2205/4885TSHR 365/4885MAPK1 3269/4885 |
| US-20250289821-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | ALDH1A1 2205/4885TSHR 365/4885MAPK1 3269/4885 |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | ALDH1A1 2205/4885TSHR 365/4885MAPK1 3269/4885 |
| US-11084817-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | ALDH1A1 2205/4885TSHR 365/4885MAPK1 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.